• In recent days, Guardant Health released a colorectal cancer screening awareness video featuring actor and cancer advocate Patrick Dempsey, spotlighting its FDA-approved Shield blood test, while also scheduling presentations at upcoming investor conferences. The company is also preparing to report quarterly earnings after the market close, following prior revenue of US$301.7 million that exceeded analyst expectations.
• A distinctive aspect of this news is that Shield is currently the only FDA-approved blood test included in major colorectal cancer screening guidelines, which may set Guardant Health apart in the expanding non-invasive screening market.
• We’ll now examine how heightened attention on Shield’s guideline-backed blood test and the upcoming earnings report reshape Guardant Health’s investment narrative.

AI is about to change healthcare. These 41 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.

Guardant Health Investment Narrative Recap

To own Guardant Health, you need to believe blood based cancer diagnostics, led by Shield, can justify today’s rich valuation and heavy cash burn. In the near term, the key catalyst is how Shield’s early commercial traction shows up in upcoming earnings, while the biggest risk remains sustained losses and potential future dilution. The Patrick Dempsey campaign and guideline-backed positioning raise awareness, but on their own do not materially change that risk reward balance yet.

The most relevant update here is Guardant’s upcoming earnings report after a quarter in which revenue reached US$301.7 million and topped analyst expectations. With analysts now watching for a projected quarterly revenue of about US$316 million and a loss per share of roughly US$0.40, the results could clarify whether heightened attention on Shield is translating into screening revenue that supports the current spending run rate and expectations for the wider precision oncology portfolio...

Guardant Health's narrative projects $2.5 billion revenue and $3.9 million earnings by 2029.

Uncover how Guardant Health's forecasts yield a $171.08 fair value, a 12% upside to its current price.

Exploring Other Perspectives

By contrast, the most pessimistic analysts saw revenue only reaching about US$1.7 billion by 2029 with no profitability in sight, so when you weigh Shield’s guideline backed progress against concerns about delayed cash flow breakeven and rising fixed costs, you can see how reasonable people can look at the same headlines and arrive at very different conclusions.

Explore 6 other fair value estimates on Guardant Health - why the stock might be worth less than half the current price!

Form Your Own Verdict

Don't just follow the ticker - dig into the data and build a conviction that's truly your own.

• A great starting point for your Guardant Health research is our analysis highlighting 2 key rewards and 2 important warning signs that could impact your investment decision.
• Our free Guardant Health research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Guardant Health's overall financial health at a glance.

Interested In Other Possibilities?

Don't miss your shot at the next 10-bagger. Our latest stock picks just dropped:

• Capitalize on the AI infrastructure supercycle with our selection of the 56 best 'picks and shovels' of the AI gold rush converting record-breaking demand into massive cash flow.
• The future of work is here. Discover the 34 top robotics and automation stocks leading the charge in AI-driven automation and industrial transformation.
• Uncover the next big thing with 21 elite penny stocks that balance risk and reward.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.